Stocks Health care ODTX
NASDAQ · Health careOdyssey Therapeutics, Inc. (ODTX)
At September 30, 2026 it held $80.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Odyssey Therapeutics, Inc.
- Net worth
- Odyssey Therapeutics, Inc. has a market value (market cap) of $920.3M at the latest share price, and shareholders' equity of $375.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Odyssey Therapeutics, Inc.'s next report is expected around January 13, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Odyssey Therapeutics, Inc. does
Odyssey Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ODTX.
Earnings: every quarter and the next report date
Latest SEC filings
What Odyssey Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- November 4, 2026
- October 20, 2026
- September 9, 2026
- August 6, 2026
- August 4, 2026
- June 23, 2026
- June 17, 2026
- June 17, 2026
Insider trades
What the people running Odyssey Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 11, 2026 | Tpg Gp A, LLCFormer 10% Owner | Other changeindirect | 423,111 | - |
| May 11, 2026 | Tpg Gp A, LLCFormer 10% Owner | Other changeindirect | 2,351 | $42.3K |
| May 11, 2026 | Tpg Gp A, LLCFormer 10% Owner | Exercised optionsindirect | 1,880,497 | - |
| May 11, 2026 | Tpg Gp A, LLCFormer 10% Owner | Boughtindirect | 1,388,889 | $25M |
| May 11, 2026 | Opipari Anthony W.See Remarks | Exercised options | 6,965 | - |
| May 11, 2026 | Opipari Anthony W.See Remarks | Exercised options | 541 | - |
| May 11, 2026 | Opipari Anthony W.See Remarks | Shares withheld for tax | 4 | $72 |
| May 11, 2026 | Glick Gary DSee Remarks, Director | Exercised options | 27,386 | - |
Who owns ODTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 10.2% | June 5, 2026 |
| SR One Capital Management, LLC13D, may seek influence with 8 related filers | 8% | May 18, 2026 |
| Jeito II S.L.P.13D, may seek influence with 3 related filers | 7.8% | May 15, 2026 |
| Tpg GP A, LLC13D, may seek influence with 2 related filers | 7.8% | May 18, 2026 |
| Lightspeed Venture Partners XV-B (Ignite), L.P.13G, passive with 2 related filers | 7.6% | May 18, 2026 |
| Dimension Management, L.P.13D, may seek influence with 6 related filers | 7.1% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 58 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 5,179,262 | new |
| SR One Capital Management, LP | 3,794,883 | new |
| Tpg GP A, LLC | 3,690,146 | new |
| Lightspeed Management Company, L.L.C. | 3,608,443 | new |
| Orbimed Advisors LLC | 3,001,198 | new |
| Sanofi | 1,991,918 | new |
| Deerfield Management Company, L.P. | 1,046,139 | new |
| Sands Capital Alternatives, LLC | 875,000 | new |
| Hhlr Advisors, Ltd. | 831,656 | new |
| General Catalyst Group Management, LLC | 810,272 | new |
| Affinity Asset Advisors, LLC | 766,346 | new |
| Adage Capital Partners GP, L.L.C. | 725,000 | new |
| Vanguard Capital Management LLC | 720,440 | new |
| Foresite Capital Management V, LLC | 713,105 | new |
| Vivo Capital, LLC | 575,000 | new |
| EcoR1 Capital, LLC | 555,555 | new |
| Logos Global Management LP | 521,736 | new |
| Marshall Wace, Llp | 492,697 | new |
| Catalio Capital Management, LP | 457,839 | new |
| Redmile Group, LLC | 425,000 | new |
Insiders
9 insiders reported holding 12,171,365 shares in total, about $233.1M at the last price.
| Holder | Shares |
|---|---|
| Tpg Gp A, LLCFormer 10% Owner | 3,690,1463,690,146 held indirectly |
| Li Nan (LN)Director | 3,333,5163,333,516 held indirectly |
| Dimension Capital II, L.P.Director | 3,333,516 |
| Sr One Capital Management, LLC10% owner | 1,014,8511,014,851 held indirectly |
| Glick Gary DSee Remarks, Director | 415,973 |
| Leiden Jeffrey MDirector | 301,84231,644 held indirectly |
| Haas JasonChief Financial Officer | 62,908 |
| Chu ShelleyDirector | 11,111 |
| Opipari Anthony W.See Remarks | 7,502 |
Questions about ODTX
What does Odyssey Therapeutics, Inc. do?
Odyssey Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ODTX. Its shares trade on NASDAQ under the ticker ODTX.
What is Odyssey Therapeutics, Inc.'s net worth?
Odyssey Therapeutics, Inc. has a market value (market cap) of $920.3M at the latest share price, and shareholders' equity of $375.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Odyssey Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Odyssey Therapeutics, Inc.'s next earnings report?
Odyssey Therapeutics, Inc.'s next report is expected around January 13, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ODTX with
Follow ODTX
Get an email when Odyssey Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Odyssey Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.